Sugi Predict

Sugi Predict / Targets / NEK3

NEK3

Serine/threonine-protein kinase Nek3 · P51956 · NEK3 on Sugi Atlas →

7,679 patent compounds predicted against NEK3, 6,704 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Volasertib Volasertib (SCHEMBL738946) 1.00 2/20
Volasertib Volasertib (SCHEMBL2169101) 1.00 2/20
SCHEMBL738553 SCHEMBL738553 0.83 2/20
SCHEMBL1843960 SCHEMBL1843960 0.82 2/20
SCHEMBL1843961 SCHEMBL1843961 0.82 2/20
SCHEMBL1845289 SCHEMBL1845289 0.82 2/20
SCHEMBL738942 SCHEMBL738942 0.78 2/20
SCHEMBL2879117 SCHEMBL2879117 0.69 2/20
SCHEMBL2880178 SCHEMBL2880178 0.65 2/20
SCHEMBL3490296 SCHEMBL3490296 0.63 2/20
SCHEMBL3490301 SCHEMBL3490301 0.63 2/20
SCHEMBL3490304 SCHEMBL3490304 0.63 2/20
SCHEMBL1203630 SCHEMBL1203630 0.60 2/20
SCHEMBL1203741 SCHEMBL1203741 0.60 2/20
SCHEMBL1202880 SCHEMBL1202880 0.58 2/20
SCHEMBL1669713 SCHEMBL1669713 0.58 2/20
SCHEMBL861947 SCHEMBL861947 0.57 2/20
SCHEMBL1667984 SCHEMBL1667984 0.55 2/20
SCHEMBL1204309 SCHEMBL1204309 0.54 2/20
SCHEMBL2358356 SCHEMBL2358356 0.52 2/20

Clinical trials — most relevant to NEK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer PHASE2COMPLETED
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor PHASE2RECRUITING
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer PHASE2COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer PHASE1RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm nanUNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
18F-FDG PET/TC in TIR3A e TIR3B nanENROLLING_BY_INVITATION
Implementing Patients´ Competence in Oral Breast Cancer Therapy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NEK3 binder may also engage these)

ProteinNameSimilarity
Q9R0A5 — 0.994 Q9R0A5 →
Q8RXT4 — 0.993 Q8RXT4 →
Q6YY75 — 0.993 Q6YY75 →
STK33 Serine/threonine-protein kinase 33 0.993 landscape →
Q8RX66 — 0.992 Q8RX66 →
Q63553 — 0.992 Q63553 →
Q2QMH1 — 0.992 Q2QMH1 →
SNRK SNF-related serine/threonine-protein kinase 0.992 landscape →
Q9Z2R9 — 0.991 Q9Z2R9 →
Q4R8E0 — 0.991 Q4R8E0 →
B2GUY1 — 0.991 B2GUY1 →
Q9CAU7 — 0.991 Q9CAU7 →
Q0VD22 — 0.991 Q0VD22 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.990 landscape →
Q641K5 — 0.990 Q641K5 →
Q5TKR9 — 0.990 Q5TKR9 →
Q9LHI7 — 0.990 Q9LHI7 →
Q09831 — 0.990 Q09831 →
Q3ULB5 — 0.990 Q3ULB5 →
Q7TNL3 — 0.990 Q7TNL3 →
Q5R667 — 0.990 Q5R667 →
A7MBB4 — 0.990 A7MBB4 →
Q66I46 — 0.990 Q66I46 →
Q94C95 — 0.990 Q94C95 →
Q9TTK0 — 0.990 Q9TTK0 →
G5EFD2 — 0.990 G5EFD2 →
Q4R7T5 — 0.989 Q4R7T5 →
Q17QV9 — 0.989 Q17QV9 →
A7A1P0 — 0.989 A7A1P0 →
A8WRV1 — 0.989 A8WRV1 →